Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Gynecology · Genitourinary Syndrome of Menopause

Long-Term Management and Building Your Care Team

At a Glance

Genitourinary Syndrome of Menopause (GSM) is a chronic condition caused by permanent hormonal changes. It requires ongoing, consistent treatment, such as low-dose vaginal estrogen, to maintain symptom relief. Building a care team with a menopause specialist helps achieve long-term comfort.

Because Genitourinary Syndrome of Menopause (GSM) is a chronic and progressive condition, it is not something that you “cure” and then move on from. Instead, managing GSM is about finding a sustainable rhythm that protects your tissue health and quality of life for the long haul [1][2].

The Maintenance Mindset

The most important thing to understand about GSM is that it is tied to the permanent hormonal shift of menopause. Unlike hot flashes, which may eventually stop on their own, the tissue changes in GSM do not [3].

  • Consistency is Key: If you stop your treatment—whether it is local estrogen, DHEA, or even regular moisturizing—your symptoms will almost certainly return because the underlying estrogen deficiency is still there [3][1].
  • Long-Term Safety: For many women, low-dose vaginal treatments are safe to use indefinitely [4]. Guidelines suggest that you shouldn’t be forced to stop a treatment that is working for you, provided you and your doctor continue to monitor your health [5][6].

Building Your Care Team

Managing a chronic condition like GSM often requires more than just a standard annual exam. You may benefit from a multidisciplinary team—a group of different specialists working together to address your symptoms [7][8].

  • The Menopause Specialist: Look for a Menopause Society Certified Practitioner (MSCP) [9]. This certification means the provider has passed a competency exam and is dedicated to following the most current, evidence-based guidelines for menopause care [9].
  • Pelvic Floor Physical Therapist (PFPT): If you have had chronic pain, your pelvic muscles may have learned to “guard” or stay tense, which can make intercourse or even sitting painful [10]. A PFPT can help you “retrain” these muscles to relax, which can significantly improve pain and sexual function [11][12].

When to Change Course

You should expect to see an improvement in your comfort or natural lubrication within a few weeks of starting treatment, but fully reversing tissue elasticity and architectural changes often takes 2 to 12 weeks of consistent therapy [13]. If you do not see improvement after an adequate trial period, it is time to reassess [14].

  • Rule Out “Mimics”: If standard GSM treatments aren’t working, your doctor should investigate other possibilities, such as Desquamative Inflammatory Vaginitis (DIV), Vulvodynia, or Lichen Sclerosus [14][15].
  • Listen to Your Body: You are the expert on your own comfort. If your symptoms are being dismissed as “just part of aging” or if your current treatment isn’t giving you the quality of life you deserve, seek a second opinion from a certified menopause specialist [8][16].

Monitoring Your Progress

Regular follow-ups (often every 6 to 12 months once you are stable) are important to ensure your treatment dose is still correct and to check for any new changes in your urogenital health [7]. By staying proactive and consistent, you can manage GSM effectively and maintain your physical comfort and sexual health throughout your postmenopausal years.

Common questions in this guide

Do I need to use GSM treatments forever?
Yes, because Genitourinary Syndrome of Menopause is tied to permanent hormonal changes. If you stop your treatment, your symptoms of dryness and discomfort will likely return since the underlying estrogen deficiency is still present.
Is it safe to use vaginal estrogen long-term?
For most women, low-dose vaginal treatments like estrogen are safe to use indefinitely. Current guidelines suggest you can continue a treatment that works for you as long as you maintain regular check-ups with your doctor.
What kind of doctor specializes in treating GSM?
Look for a Menopause Society Certified Practitioner (MSCP). These specialists have passed competency exams and are dedicated to following the most current, evidence-based guidelines for managing menopause symptoms and genitourinary health.
How long does it take for vaginal estrogen or DHEA to work?
You may notice improvements in comfort and natural lubrication within a few weeks. However, it often takes two to twelve weeks of consistent therapy to fully restore vaginal tissue elasticity and reverse structural changes.
What if my GSM symptoms do not improve with treatment?
If standard treatments do not provide relief within an adequate trial period, your doctor should investigate other conditions. Symptoms that mimic GSM can be caused by desquamative inflammatory vaginitis (DIV), vulvodynia, or lichen sclerosus.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are you a Menopause Society Certified Practitioner (MSCP), or do you have a specific focus on treating genitourinary health in postmenopause?
  2. 2.Can you refer me to a Pelvic Floor Physical Therapist who has experience working with patients who have GSM?
  3. 3.What is our long-term plan for monitoring my symptoms, and how often should I come in for follow-up exams?
  4. 4.If my current treatment doesn't provide enough relief within three months, what is the next step for ruling out other conditions like DIV or Vulvodynia?
  5. 5.Is there any medical reason why I would need to stop my vaginal treatment after a certain number of years, or can I continue as long as it is working?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.

    Kovacevic N, Cilensek I, Merlo S, Segedin B

    Radiology and oncology 2023; (57(3)):292-298 doi:10.2478/raon-2023-0038.

    PMID: 37494601
  2. 2

    Genitourinary Syndrome of Menopause.

    Valadares ALR, Kulak Junior J, Paiva LHSDC, et al.

    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2022; (44(3)):319-324 doi:10.1055/s-0042-1748463.

    PMID: 35576939
  3. 3

    Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.

    Kaunitz AM, Pinkerton JV, Manson JE

    Menopause (New York, N.Y.) 2019; (26(4)):338-340 doi:10.1097/GME.0000000000001313.

    PMID: 30789455
  4. 4

    Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms.

    Hirschberg AL

    Climacteric : the journal of the International Menopause Society 2025; (28(4)):400-407 doi:10.1080/13697137.2025.2514029.

    PMID: 40531325
  5. 5

    A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.

    Biehl C, Plotsker O, Mirkin S

    Menopause (New York, N.Y.) 2019; (26(4)):431-453 doi:10.1097/GME.0000000000001221.

    PMID: 30363010
  6. 6

    Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide.

    Hirschberg AL, Bitzer J, Cano A, et al.

    Maturitas 2021; (148()):55-61 doi:10.1016/j.maturitas.2021.04.005.

    PMID: 33896654
  7. 7

    Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer.

    Ferguson D, Pederson H, Kling JM

    Drugs & aging 2026; (43(3)):211-221 doi:10.1007/s40266-026-01287-9.

    PMID: 41758440
  8. 8

    Update on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.

    Cuccu I, Golia D'Augè T, Firulli I, et al.

    Life (Basel, Switzerland) 2024; (14(11)) doi:10.3390/life14111504.

    PMID: 39598302
  9. 9

    Are clinics not affiliated with a Menopause Society Certified Practitioner more likely to offer guideline-nonconcordant treatment compared to clinics affiliated with a Menopause Society Certified Practitioner?

    Marino JM, Stanley EE, Ahrendt H, Pope R

    Menopause (New York, N.Y.) 2024; (31(9)):764-768 doi:10.1097/GME.0000000000002392.

    PMID: 38980733
  10. 10

    Clinical Practice Guidelines for Managing Genitourinary Symptoms Associated With Menopause.

    Christmas M, Huguenin A, Iyer S

    Clinical obstetrics and gynecology 2024; (67(1)):101-114 doi:10.1097/GRF.0000000000000833.

    PMID: 38126460
  11. 11

    Physical Therapy Intervention for Women With Dyspareunia: A Randomized Clinical Trial.

    Schvartzman R, Schvartzman L, Ferreira CF, et al.

    Journal of sex & marital therapy 2019; (45(5)):378-394 doi:10.1080/0092623X.2018.1549631.

    PMID: 30640585
  12. 12

    Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study.

    Cyr MP, Dumoulin C, Bessette P, et al.

    Gynecologic oncology 2020; (159(3)):778-784 doi:10.1016/j.ygyno.2020.09.001.

    PMID: 33010968
  13. 13

    Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.

    Pinkerton JV, Kaunitz AM, Manson JE

    Menopause (New York, N.Y.) 2017; (24(12)):1329-1332 doi:10.1097/GME.0000000000000996.

    PMID: 29040220
  14. 14

    Assessment and Treatment of Vaginitis.

    Mitchell CM

    Obstetrics and gynecology 2024; (144(6)):765-781 doi:10.1097/AOG.0000000000005673.

    PMID: 38991218
  15. 15

    Evaluation and Management of Vaginitis.

    Marnach ML, Wygant JN, Casey PM

    Mayo Clinic proceedings 2022; (97(2)):347-358 doi:10.1016/j.mayocp.2021.09.022.

    PMID: 35120697
  16. 16

    The Enablers and Barriers to Accessing Women's Health and Wellbeing Services for Women Aged 40-65 Years: A Qualitative Study.

    Simmons K, Hyde J, Harmanci D, et al.

    Community health equity research & policy 2026; (46(4)):413-431 doi:10.1177/2752535X251358919.

    PMID: 40653685

This content provides educational information about managing Genitourinary Syndrome of Menopause. Always consult your healthcare provider or a certified menopause specialist before changing or stopping your treatment plan.

Get notified when new evidence is published on postmenopausal atrophic vaginitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.